Therapeutic efficacy of humanized anti-IL-6-receptor antibody in systemic juvenile idiopathic arthritis.

被引：0
|
作者：
Yokota, S
Miyamae, T
Imagawa, T
Nishimoto, N
Yoshizaki, K
Hirsch, R
Mori, M
机构：
来源：
ARTHRITIS AND RHEUMATISM | 2001年 / 44卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1432
引用
收藏
页码：S291 / S291
页数：1
相关论文
共 50 条
  • [1] Long-term therapeutic efficacy of humanized anti-il 6-receptor antibody for systemic juvenile idiopathic arthritis.
    Yokota, S
    Miyamae, TK
    Imagawa, T
    Nishimoto, N
    Yoshizaki, K
    Mori, M
    Hirsch, R
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S479 - S479
  • [2] Anti-IL-6 receptor antibody therapy of a girl with severe systemic juvenile idiopathic arthritis.
    Yamazaki, T
    Agematsu, K
    Tanaka, M
    Nagumo, H
    Yasui, K
    Komiyama, A
    CLINICAL IMMUNOLOGY, 2002, 103 (03) : S81 - S81
  • [3] Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis
    Imagawa, Tomoyuki
    Yokota, Shumpei
    Mori, Masaaki
    Miyamae, Takako
    Takei, Syuji
    Imanaka, Hiroyuki
    Nerome, Yasuhito
    Iwata, Naomi
    Murata, Takuji
    Miyoshi, Mari
    Nishimoto, Norihiro
    Kishimoto, Tadamitsu
    MODERN RHEUMATOLOGY, 2012, 22 (01) : 109 - 115
  • [4] Therapeutic Efficacy of Humanized Recombinant Anti-Interleukin-6 Receptor Antibody in Children With Systemic-Onset Juvenile Idiopathic Arthritis
    Yokota, Shumpei
    Miyamae, Takako
    Imagawa, Tomoyuki
    Iwata, Naomi
    Katakura, Shigeki
    Mori, Masaaki
    Woo, Patricia
    Nishimoto, Norihiro
    Yoshizaki, Kazuyuki
    Kishimoto, Tadamitsu
    ARTHRITIS AND RHEUMATISM, 2005, 52 (03): : 818 - 825
  • [5] Efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody; in patients with polyarticular or oligoarticular onset juvenile idiopathic arthritis.
    Imagawa, Tomoyuki
    Mori, Masaaki
    Takei, Syuji
    Kawano, Yoshifumi
    Iwata, Naomi
    Miyoshi, Mari
    Murata, Takuji
    Nishimoto, Norihiro
    Kishimoto, Tadamitsu
    Yokota, Shumpei
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S168 - S168
  • [6] Radiological Evaluation of Systemic Juvenile Idiopathic Arthritis Treated with Tocilizumab, An Anti-IL6 Receptor Monoclonal Antibody.
    Aoki, Chie
    Inaba, Yutaka
    Imagawa, Tomoyuki
    Miyamae, Takako
    Mori, Masaaki
    Saito, Tomoyuki
    Yokota, Shumpei
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1031 - S1032
  • [7] Long-term therapeutic experience of humanized anti-IL-6 receptor monoclonal antibody (aIL-6R Mab) in systemic-onset juvenile idiopathic arthritis (So-JIA).
    Yokota, S
    Imagawa, T
    Miyamae, T
    Mori, M
    Nishimoto, N
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S438 - S438
  • [8] Long-term treatment of systemic onset juvenile idiopathic arthritis (SO-JIA) with humanized anti-IL-6 receptor monoclonal antibody, tocilizumab (Actemra®)
    Yokota, S
    Miyamae, T
    Kurosawa, R
    Ozawa, R
    Imagawa, T
    Mori, M
    Nishimoto, N
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S725 - S725
  • [9] Phase II trial of anti-IL-6 receptor antibody (MRA) for children with systemic-onset juvenile idiopathic arthritis
    Yokota, S
    Miyamae, T
    Imagawa, T
    Iwata, N
    Katakura, S
    Mori, M
    Nishimoto, N
    Yoshizaki, K
    Woo, P
    Hirsch, R
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S429 - S429
  • [10] Catch-up growth in severe systemic-onset juvenile idiopathic arthritis: Long-term treatment with humanized anti-IL6 receptor monoclonal antibody
    Imagawa, T
    Miyamae, T
    Umebayashi, H
    Kurosawa, R
    Katakura, S
    Mori, M
    Nishimoto, N
    Yokota, S
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S91 - S92
12345